Cite
588P Genomic landscape of acquired resistance to first-line (1L) anti-EGFR treatment in metastatic colorectal cancer (mCRC) beyond the classical EGFR pathway: Findings from the PLATFORM-B study.
MLA
Martelli, V., et al. “588P Genomic Landscape of Acquired Resistance to First-Line (1L) Anti-EGFR Treatment in Metastatic Colorectal Cancer (MCRC) beyond the Classical EGFR Pathway: Findings from the PLATFORM-B Study.” Annals of Oncology, vol. 35, Sept. 2024, pp. S474–75. EBSCOhost, https://doi.org/10.1016/j.annonc.2024.08.657.
APA
Martelli, V., Barrull, J. V., Rodriguez, C. F., Toledo, R. D. A., Gibert, J., Alfonso, P. G., Paez, D., Alonso-Orduna, V., Gomez España, M. A., Vivas, C. S., Ogaya, G. D., Fernandez, M. E. E., Garcia-Carbonero, R., Monteagudo, R. F., Mozo, J. L. M., Paricio, B. B., Tabernero, J., Soler, R. S., Aguilar, E. A., & Viladot, C. M. (2024). 588P Genomic landscape of acquired resistance to first-line (1L) anti-EGFR treatment in metastatic colorectal cancer (mCRC) beyond the classical EGFR pathway: Findings from the PLATFORM-B study. Annals of Oncology, 35, S474–S475. https://doi.org/10.1016/j.annonc.2024.08.657
Chicago
Martelli, V., J. Vidal Barrull, C. Fernandez Rodriguez, R.D.A. Toledo, J. Gibert, P. García Alfonso, D. Paez, et al. 2024. “588P Genomic Landscape of Acquired Resistance to First-Line (1L) Anti-EGFR Treatment in Metastatic Colorectal Cancer (MCRC) beyond the Classical EGFR Pathway: Findings from the PLATFORM-B Study.” Annals of Oncology 35 (September): S474–75. doi:10.1016/j.annonc.2024.08.657.